Dale B. Schenk
#165,548
Most Influential Person Now
Dale B. Schenk's AcademicInfluence.com Rankings
Dale B. Schenkbiology Degrees
Biology
#13397
World Rank
#16942
Historical Rank
Neuroscience
#2319
World Rank
#2383
Historical Rank
Biochemistry
#2344
World Rank
#2493
Historical Rank
Download Badge
Biology
Dale B. Schenk's Degrees
- PhD Biochemistry University of California, Berkeley
- Bachelors Chemistry University of California, Davis
Why Is Dale B. Schenk Influential?
(Suggest an Edit or Addition)Dale B. Schenk's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse (1999) (3280)
- Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein (1995) (2557)
- Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease (2000) (2020)
- Amyloid β-peptide is produced by cultured cells during normal metabolism (1992) (1799)
- Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids (1992) (1696)
- Purification and cloning of amyloid precursor protein β-secretase from human brain (1999) (1649)
- Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice (1997) (1324)
- Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* (2006) (1073)
- Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain (2000) (867)
- Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. (2003) (831)
- BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. (2001) (734)
- Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease (1995) (632)
- The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway (1995) (580)
- Aβ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse (1997) (547)
- Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide (1993) (511)
- Amyloid beta-peptide is produced by cultured cells during normal metabolism. (1992) (510)
- Secreted form of amyloid β protein precursor is involved in the growth regulation of fibroblasts (1989) (494)
- Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy (2001) (486)
- Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease (2005) (478)
- High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. (1998) (456)
- The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II (1989) (444)
- Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease (1997) (435)
- Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning (2002) (424)
- Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones. (1988) (414)
- Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein and Alzheimer’s Disease (1996) (407)
- Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology (2003) (402)
- Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease (2005) (385)
- Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease (2011) (372)
- Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. (1994) (350)
- Rapid Communication: Characterization of β‐Amyloid Peptide from Human Cerebrospinal Fluid (1993) (341)
- Detection of Phosphorylated Ser262 in Fetal Tau, Adult Tau, and Paired Helical Filament Tau (*) (1995) (334)
- Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy (2002) (328)
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease (2009) (327)
- Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. (2005) (268)
- Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models (2014) (263)
- Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease (1995) (222)
- The Role of Biomarkers in Clinical Trials for Alzheimer Disease (2006) (216)
- Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. (2002) (188)
- First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers (2016) (182)
- A&bgr; Species Removal After A&bgr;42 Immunization (2006) (178)
- Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–&agr;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial (2018) (165)
- β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease (2005) (163)
- Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. (1997) (158)
- First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. (2016) (157)
- Amyloid deposition in the hippocampus and entorhinal cortex: Quantitative analysis of a transgenic mouse model (2003) (150)
- Kunitz Protease Inhibitor‐Containing Amyloid β Protein Precursor Immunoreactivity in Alzheimer's Disease (1992) (143)
- The amyloid precursor protein is concentrated in neuronal lysosomes in normal and Alzheimer disease subjects (1989) (136)
- Current progress in beta-amyloid immunotherapy. (2004) (135)
- Increased β‐amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670/671 mutation (1994) (131)
- Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. (2004) (129)
- Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease (2014) (122)
- Cerebrospinal fluid levels of amyloid β‐protein in alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein e genotype (1995) (122)
- Atrial natriuretic peptide mRNA is regulated by glucocorticoids in vivo. (1986) (118)
- Aβ42 immunization in Alzheimer's disease generates Aβ N‐terminal antibodies (2005) (118)
- Truncated atrial natriuretic peptide analogs. Comparison between receptor binding and stimulation of cyclic GMP accumulation in cultured vascular smooth muscle cells. (1986) (117)
- Distinct atrial natriuretic factor receptor sites on cultured bovine aortic smooth muscle and endothelial cells. (1985) (112)
- Immunotherapy Reduces Vascular Amyloid-β in PDAPP Mice (2008) (109)
- Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ (2009) (104)
- Treatment strategies targeting amyloid β-protein. (2012) (104)
- Characterization of beta-amyloid peptide from human cerebrospinal fluid. (1993) (103)
- On the mechanism of nonspecific inhibitors of protein aggregation: dissecting the interactions of alpha-synuclein with Congo red and lacmoid. (2009) (101)
- Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family (1994) (93)
- Mice as models: transgenic approaches and Alzheimer's disease. (2006) (93)
- Appearance of Sodium Dodecyl Sulfate-Stable Amyloid β-Protein (Aβ) Dimer in the Cortex During Aging (1999) (91)
- Selective vulnerability of dentate granule cells prior to amyloid deposition in PDAPP mice: digital morphometric analyses. (2004) (91)
- Purification and subunit composition of atrial natriuretic peptide receptor. (1987) (89)
- Cerebrospinal Fluid Levels of Amyloid Precursor Protein and Amyloid β-Peptide in Alzheimer’s Disease and Major Depression – Inverse Correlation with Dementia Severity (1998) (87)
- Elevated Alpha-Synuclein Impairs Innate Immune Cell Function and Provides a Potential Peripheral Biomarker for Parkinson's Disease (2013) (85)
- beta-peptide immunization: a possible new treatment for Alzheimer disease. (2000) (84)
- Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein. (2013) (80)
- A novel presenilin‐1 mutation: Increased β‐amyloid and neurofibrillary changes (1997) (77)
- Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. (2005) (73)
- Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy (2017) (72)
- Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease. (1995) (71)
- Identification of the receptor for atrial natriuretic factor on cultured vascular cells. (1985) (70)
- Differential Effects of a Rab6 Mutant on Secretory Versus Amyloidogenic Processing of Alzheimers -Amyloid Precursor Protein (*) (1996) (69)
- Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease (2009) (68)
- Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. (2005) (66)
- Identification of small-molecule binding pockets in the soluble monomeric form of the Aβ42 peptide. (2013) (65)
- AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils (2012) (65)
- Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse (2008) (63)
- Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope Specific (2012) (61)
- Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit (2012) (58)
- Prevention and Reduction of AD‐type Pathology in PDAPP Mice Immunized with Aβ1–42 (2000) (58)
- Beyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease (2013) (57)
- Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities (2013) (57)
- Identification of γ-Secretase Inhibitor Potency Determinants on Presenilin* (2008) (54)
- Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats (1995) (53)
- Amyloid-beta neurotoxicity is mediated by FISH adapter protein and ADAM12 metalloprotease activity. (2005) (52)
- A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium (2008) (50)
- Revision of the criteria for Alzheimer's disease: A symposium (2011) (49)
- Amyloid β-Protein Precursor Juxtamembrane Domain Regulates Specificity of γ-Secretase-dependent Cleavages* (2007) (49)
- Monoclonal antibodies to rat Na+,K+-ATPase block enzymatic activity. (1983) (48)
- Increased T Cell Recruitment to the CNS after Amyloid β1–42 Immunization in Alzheimer's Mice Overproducing Transforming Growth Factor-β1 (2006) (48)
- Labeling of Cerebral Amyloid In Vivo with a Monoclonal Antibody (1994) (47)
- Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease (2010) (46)
- Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies (2015) (46)
- Concentrations of amyloid-β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease (1994) (46)
- Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid β-related Behavioral Deficits in a Mouse Model of Alzheimer Disease (2009) (45)
- Analysis and Quantitation of the β‐Amyloid Precursor Protein in the Cerebrospinal Fluid of Alzheimer's Disease Patients with a Monoclonal Antibody‐Based Immunoassay (1991) (45)
- Amyloid β-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation (1995) (42)
- Early risk assessment for Alzheimer's disease (2009) (42)
- Use of a monoclonal antibody to quantify (Na+,K+)-ATPase activity and sites in normal and regenerating rat liver. (1984) (41)
- Monoclonal antibodies to surfactant proteins SP28-36 label canine type II and nonciliated bronchiolar cells by immunofluorescence. (1988) (40)
- Accumulation of Amyloid β-Protein in the Low-Density Membrane Domain Accurately Reflects the Extent of β-Amyloid Deposition in the Brain (2001) (39)
- Aβ Immunotherapy: Lessons Learned for Potential Treatment of Alzheimer’s Disease (2006) (38)
- Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice (2012) (38)
- Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. (1999) (37)
- Rat hepatic (Na+, K+)-ATPase: alpha-subunit isolation by immunoaffinity chromatography and structural analysis by peptide mapping. (1986) (36)
- The role of microglia in Alzheimer’s disease: friend or foe? (2002) (35)
- Characterization of the atrial natriuretic peptide clearance receptor using a vaccinia virus expression vector. (1988) (34)
- Hepatic (Na+, K+)‐ATPase: A current view of its structure, function and localization in rat liver as revealed by studies with monoclonal antibodies (1985) (34)
- Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab (2014) (32)
- Isolation of baculovirus-derived secreted and full-length beta-amyloid precursor protein. (1991) (32)
- A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. (2005) (30)
- Potential treatment opportunities for Alzheimer’s disease through inhibition of secretases and Aβ immunization (2001) (29)
- Alzheimer’s Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned? (2006) (29)
- Altered APP Processing in PDAPP (Val717 → Phe) Transgenic Mice Yields Extended-Length Aβ Peptides. (2005) (29)
- Chronic γ-secretase inhibition reduces amyloid plaque-associated instability of pre- and postsynaptic structures (2013) (29)
- Alzheimer's disease: A partner for presenilin (2000) (29)
- A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes. (1997) (28)
- Hopes remain for an Alzheimer's vaccine (2004) (27)
- β-Amyloid Inhibits E-S Potentiation through Suppression of Cannabinoid Receptor 1-Dependent Synaptic Disinhibition (2014) (26)
- Identification of loci determining susceptibility to the lethal effects of amyloid precursor protein transgene overexpression. (2004) (25)
- Identification of gamma-secretase inhibitor potency determinants on presenilin. (2008) (25)
- Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide (2013) (23)
- 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis † (2016) (22)
- Immunotherapy with β-Amyloid for Alzheimer's Disease: A New Frontier (2001) (22)
- Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting (2018) (22)
- Altered APP processing in PDAPP (Val717 --> Phe) transgenic mice yields extended-length Abeta peptides. (2005) (22)
- Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages. (2007) (20)
- Recombinant expression of a secreted form of the atrial natriuretic peptide clearance receptor. (1989) (20)
- Accumulation of amyloid beta-protein in the low-density membrane domain accurately reflects the extent of beta-amyloid deposition in the brain. (2001) (20)
- Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein Protect Against Diverse α-Synuclein Mediated Dysfunctions (2019) (17)
- Erratum: Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology (Proceedings of the National Academy of Science of the United States of America (February 18, 2003) 100, 4 (2023-2028)) (2004) (16)
- Recent Advances in the Understanding of the Processing of APP to Beta Amyloid Peptide (2000) (16)
- Generation and Characterization of Anti-AA Amyloid-Specific Monoclonal Antibodies (2011) (13)
- NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study (2016) (13)
- Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery (2006) (11)
- Therapeutic Approaches Related to Amyloid-β Peptide and Alzheimer′ s Disease (1996) (9)
- Evidence that Enzyme Processivity Mediates Differential Aβ Production by PS1 and PS2 (2013) (9)
- Current challenges for the successful treatment and prevention of Alzheimer’s disease: Treating the pathologies of the disease to change its clinical course (2008) (8)
- Inhibitory monoclonal antibodies against rat liver alcohol dehydrogenase. (1984) (8)
- The Aβ peptide conjugate vaccine, acc-001, generates n-terminal anti- Aβ antibodies in the absence of Aβ directed t-cell responses (2011) (8)
- Truncated atrial natriuretic peptide (ANP) analogs: relationship between receptor binding and cyclic GMP accumulation (1986) (7)
- Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. (2001) (7)
- Identification of secreted beta-amyloid precursor protein binding sites on intact human fibroblasts. (1994) (6)
- Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson’s disease (2018) (6)
- Treatment of Alzheimers Disease: The Beginning of a New Era Dale Schenk, ISOA - October 5th-6th, 2005 (2006) (5)
- Treatment of Alzheimer's disease: the beginning of a new era. (2006) (4)
- The potential utility of transgenic mice harboring beta-amyloid precursor protein. (1995) (4)
- 2 Aβ42 and Tau as Markers of Alzheimer's Disease (1996) (4)
- DETECTION OF CIRCULATING FORMS OF THE β-AMYLOID PRECURSOR PROTEIN (BAPP) IN HUMAN PLASMA: 230 (1989) (3)
- The potential utility of transgenic mice harboring β-amyloid precursor protein (1995) (3)
- ANTIBODIES TO DISTINCT REGIONS OF β-AMYLOID PRECURSOR PROTEIN (βAPP) DIFFERENTIALLY LABEL ALZHEIMER DISEASE (AD) SENILE PLAQUES: 88 (1989) (3)
- A possible vaccine for treatment of Alzheimer's disease (2000) (2)
- NEOD001 Specifically Binds Aggregated Light Chain Infiltrates in Multiple Organs from Patients with AL Amyloidosis and Promotes Phagocytic Clearance of AL Aggregates in Vitro (2015) (2)
- Organ Biomarker Responses in Patients With Light Chain Amyloidosis Treated With NEOD001 Are Independent of Previous Hematologic Response (2016) (2)
- The Effect of Apolipoprotein E Genotype on Biochemical Markers of Alzheimer's Disease (1996) (2)
- (Na+,K+)-ATPase: a new assay of Na+-ATPase reveals covert anti-pump antibodies. (1982) (2)
- AA Species Removal After AA42 Immunization (2006) (2)
- A-beta-42 and tau as markers of Alzheimers disease (1996) (1)
- Quantitative Assessment of Neuronal Damage in a Transgenic Murine Model of Alzheimer's Disease (2006) (1)
- Double-Blind, Placebo-Controll ed, Single Ascending-Dose Study in Healthy Subjects With PRX002, an Anti-α-Synucl ein Monoclonal Antibody (2015) (1)
- Animal Model Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive A (cid:1) Immunotherapy on Their Clearance (2004) (1)
- Identification of -Secretase Inhibitor Potency Determinants (2008) (1)
- Roles in Alzheimer Disease Apolipoprotein E and Apolipoprotein E Receptors : Normal Biology and Subject Collection The Biology of Alzheimer Disease Animal Models of Alzheimer Disease (2012) (1)
- P4-401 Characterization of the humoral response to AN1792 immunization in AD patients (2004) (1)
- NEOD001 Demonstrates Cardiac Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction in a Phase 1/2 Study Expansion (2016) (0)
- 629 Progression of neurodegenerative Alzheimer's-like pathology in PDAPP 717 V→F transgenic mice (1996) (0)
- A method of screening for inhibitors of beta-amyloid peptide production (1994) (0)
- Expression of a functional atrial natriuretic peptide receptor from a cloned complementary dna (1987) (0)
- A method for determining inhibitors of the formation of beta-amyloid peptide (1994) (0)
- In vivo imaging of amyloid deposits in transgenic models of Alzheimer's disease using multi-photon microscopy (2000) (0)
- P4-049: The luminal juxtamembrane domain of beta-amyloid precursor protein regulates gamma-secretase-dependent cleavage (2006) (0)
- NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY (2017) (0)
- Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab (2014) (0)
- The methods and compositions which can be monitored (beta) in a cell processing -amyloidiesiasteproteiinin (1994) (0)
- What do people at risk for Alzheimer disease think about surrogate consent for research? (2006) (0)
- System in Alzheimer Disease Lysosomal - Proteasome System and the Autophagic - The Ubiquitin (2012) (0)
- Prevention and treatment of amyloid disease (2000) (0)
- 69 Preclinical and clinical considerations for abeta immunotherapy (2012) (0)
- Abstract 464: Novel Anti-Medin Antibodies Detect Medin Amyloid Deposits in the Aorta of Patients with Thoracic Aneurysms or Marfan Syndrome (2015) (0)
- IN VIVO LABELING OF ß-AMYLOID IN AGED MONKEYS (1993) (0)
- Commentary on “New directions for frontotemporal dementia drug discovery.” Do we know enough to develop meaningful treatments for frontotemporal dementia? (2008) (0)
- Patent Number : 45 Date of Patent : 4 , 745 , 055 May 17 , 1988 (2017) (0)
- Characterization and Purification of the Detergent Solubilized Atrial Natriuretic Peptide Receptor From Bovine Aortic Smooth Muscle Cells (1986) (0)
- X-ray structure of amyloid beta peptide:antibody (Abeta1-40:12A11) complex (2009) (0)
- P4-325 Engagement of microglia by anti-Aβ antibodies induces a response that is distinct from an LPS-induced inflammatory response (2004) (0)
- P3-421 Identification of structural determinants on PS-1 and PS-2 that affect inhibitor potency (2006) (0)
- A method for identifying inhibitor compounds for the release of beta-amyloid peptide (BAP) (1993) (0)
- Antibody Therapy Against β-Amyloid to Treat Alzheimer’s Disease (2003) (0)
- P4-264 Novel gamma secretase inhibitors showing potential for the treatment of Alzheimer’s Disease (2006) (0)
- to changed its screening of compounds for their ability to production of beta-amyloid peptides (1997) (0)
- Prevention and treatment of amyloidogenic disease synucleinopatisk and (2006) (0)
- An immunotherapeutic approach to the treatment of Alzheimer's disease (2001) (0)
- In vitro methods that can be monitored by the beta-amyloid precursor protein processing in a cell, diagnose, or monitor the beta-amyloid-related disease or to identify the beta-amyloid production inhibitors as well as soluble fragment of the beta-amyloid precursor protein (1994) (0)
- Methods and compositions for controlling cell treatment of the precursor beta-amyloid protein. (1993) (0)
- Synucleinopathic prevention and treatment of amyloidogenic disease (2008) (0)
- Fab fragment of 3D6 in complex with amyloid beta 1-40 (2014) (0)
- Prevention et traitement de maladies synucleinopathique et amyloidogenique (2005) (0)
- Method of identifying inhibitors of beta amyloid peptide production (1993) (0)
- 175 Inhibition of β- and γ-secretases as therapeutic targets for Alzheimer's disease (1996) (0)
- JCO.2015.63.6530.full (2016) (0)
- Prevention and treatment of diseases amyloidogenischen (2000) (0)
- O1-04-06 Identification of loci determining susceptibility to the lethal effects of APP transgene overexpression (2004) (0)
- Procedures for the identification of inhibitors of the production of the beta amyloid peptide. (1993) (0)
- Procedures for assisting the diagnosis of Alzheimer's disease by measuring the peptide (x- 41) amyloid beta and tau protein. (1995) (0)
- NEOD001 Demonstrates Organ Biomarker Responses in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Results From a Phase 1/2 Study (2017) (0)
- Aβ immunotherapy prevents and Reverses Alzheimer’s disease neuropathology (2006) (0)
- Prevention and treatment of disease synucleinopathic (2003) (0)
- Amyloid precursor protein expression and β-amyloid release in fibroblast cell lines obtained from family members with the Swedish APP670/671 mutation (1994) (0)
- Introduction to the special issue of Experimental Neurology on Alzheimer's disease (2010) (0)
- P4-409 Cellular assays for gamma secretase gamma and epsilon cleavages (2004) (0)
- Explorer Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease (2017) (0)
- S.23.04 Immunotherapy for Alzheimer's disease (2006) (0)
- CHARACTERIZATION OF SOLUBLE TRUNCATED FORMS OF THE AMYLOID PRECURSOR PROTEIN FROM HUMAN PLASMA: 148 (1990) (0)
- CRIBLAGE DE COMPOSES CAPABLES DE MODIFIER LA PRODUCTION DE PEPTIDE AMYLOIDE-β (x-≥41) (1997) (0)
- Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy (2017) (0)
- Correction for Irizarry et al., Aβ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse (1998) (0)
- (cid:98) -Peptide Immunization A Possible New Treatment for Alzheimer Disease (2000) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Dale B. Schenk?
Dale B. Schenk is affiliated with the following schools:
